Cartesian Therapeutics appoints June Seymour as Chief Accounting Officer effective Oct 27, 2025

Cartesian Therapeutics, Inc.

Annual base salary of $385,000; eligible for annual performance bonus targeted at 35% of base salary.
Receives $80,000 sign-on bonus and option to purchase 50,000 shares vesting over four years.
Ms. Seymour most recently served as SVP, Finance and Accounting at DNAnexus; previously VP Finance at Neogene Therapeutics.
CFO Blaine Davis continues as both principal financial officer and principal accounting officer.
Employment agreement includes six-month severance (base salary and pro-rata bonus) and 12-month non-compete.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.